These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10665631)

  • 1. Venlafaxine in the treatment of dysthymia: an open-label study.
    Hellerstein DJ; Batchelder ST; Little SA; Fedak MJ; Kreditor D; Rosenthal J
    J Clin Psychiatry; 1999 Dec; 60(12):845-9. PubMed ID: 10665631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine in dysthymic disorder.
    Dunner DL; Hendrickson HE; Bea C; Budech CB
    J Clin Psychiatry; 1997 Dec; 58(12):528-31. PubMed ID: 9448655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A large open-label study of venlafaxine in depressed outpatients by community-based physicians.
    Joffe RT; Marshall AM; Lee DK
    J Clin Psychiatry; 1998 Oct; 59(10):515-20. PubMed ID: 9818632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of venlafaxine in the treatment of primary dysthymia.
    Ravindran AV; Charbonneau Y; Zaharia MD; al-Zaid K; Wiens A; Anisman H
    J Psychiatry Neurosci; 1998 Nov; 23(5):288-92. PubMed ID: 9846033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.
    Ballús C; Quiros G; De Flores T; de la Torre J; Palao D; Rojo L; Gutiérrez M; Casais L; Riesgo Y
    Int Clin Psychopharmacol; 2000 Jan; 15(1):43-8. PubMed ID: 10836286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citalopram in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder S; Miozzo R; Kreditor D; Hyler S; Gangure D; Clark J
    Int Clin Psychopharmacol; 2004 May; 19(3):143-8. PubMed ID: 15107656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.
    Mazeh D; Shahal B; Aviv A; Zemishlani H; Barak Y
    Int Clin Psychopharmacol; 2007 Nov; 22(6):371-5. PubMed ID: 17917556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
    Rudolph RL; Fabre LF; Feighner JP; Rickels K; Entsuah R; Derivan AT
    J Clin Psychiatry; 1998 Mar; 59(3):116-22. PubMed ID: 9541154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    Thase ME
    J Clin Psychiatry; 1997 Sep; 58(9):393-8. PubMed ID: 9378690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial.
    de Montigny C; Silverstone PH; Debonnel G; Blier P; Bakish D
    J Clin Psychopharmacol; 1999 Oct; 19(5):401-6. PubMed ID: 10505581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venlafaxine withdrawal symptoms.
    Benazzi F
    Can J Psychiatry; 1996 Sep; 41(7):487. PubMed ID: 8884044
    [No Abstract]   [Full Text] [Related]  

  • 14. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.
    Martinotti G; Sepede G; Gambi F; Di Iorio G; De Berardis D; Di Nicola M; Onofrj M; Janiri L; Di Giannantonio M
    J Clin Psychopharmacol; 2012 Aug; 32(4):487-91. PubMed ID: 22722509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained response to open-label venlafaxine in drug-resistant major depression.
    Schweitzer I; Burrows G; Tuckwell V; Polonowita A; Flynn P; George T; Theodoros M; Mitchell P
    J Clin Psychopharmacol; 2001 Apr; 21(2):185-9. PubMed ID: 11270915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
    McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharma-Clinics. The drug of the month. Venlafaxine (Efexor)].
    Ansseau M
    Rev Med Liege; 1998 Feb; 53(2):106-8. PubMed ID: 9564231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression.
    Mitchell PB; Schweitzer I; Burrows G; Johnson G; Polonowita A
    J Clin Psychopharmacol; 2000 Aug; 20(4):483-7. PubMed ID: 10917411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial.
    Han C; Pae CU; Lee BH; Ko YH; Masand PS; Patkar AA; Joe SH; Jung IK
    Clin Drug Investig; 2008; 28(4):251-61. PubMed ID: 18345715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.